Compare

Haemonetics/$HAE

1D1W1M3M6MYTD1Y5YMAX

About Haemonetics

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The Plasma segment includes end-to-end collection technologies, automated plasmapheresis systems (such as the NexSys PCS device), and donor management software designed for commercial plasma collectors. Hospital segment includes Blood Management Technologies (hemostasis analyzers, cell salvage systems) and Interventional Technologies. And the Blood Center provides solutions and devices enabling blood centers to harvest essential components like platelets and red blood cells.
Ticker
$HAE
Sector
Health
Primary listing
NYSE
Employees
3,009

Haemonetics Metrics

BasicAdvanced
$5.5B
53.77
$2.24
0.59
-

What the Analysts think about Haemonetics

Analyst ratings (Buy, Hold, Sell) for Haemonetics stock.
Analyst projections of the future price of Haemonetics stock.

Bulls say / Bears say

CSL now expects to move all its current US plasma centres to Haemonetics’ devices and disposables by the end of 2027. A broader rollout could restore a substantial recurring consumables stream, although the financial contribution is not yet quantified. (SEC, MassDevice)
Underlying trading is improving: first-quarter organic revenue rose 5.9%, with growth in both Apheresis and MedSurg. Haemonetics raised its full-year reported revenue growth guidance to 5–8% and organic growth guidance to 4–7%. (SEC)
Persona PLUS strengthens Haemonetics’ plasma proposition by increasing plasma yield; early adopters reported gains of more than 5% versus earlier Persona technology. That customer benefit, alongside reported share gains, could help sustain demand for its collection systems and recurring disposables. (The Motley Fool, SEC)
The CSL opportunity is not yet a firm revenue commitment: the agreement is non-exclusive, rollout details remain unsettled and its scope and timing may change. Haemonetics left its fiscal 2027 guidance unchanged pending a later update on the deal’s impact. (SEC)
The business remains exposed to a small number of large buyers: its ten largest customers accounted for about 44% of fiscal 2026 revenue, and one plasma customer alone represented about 13%. That concentration makes contract losses or reduced purchasing a material risk. (SEC)
The sharp rally after the CSL announcement has raised valuation risk: a recent Seeking Alpha analysis argued the shares trade at a premium and that the deal’s upside is not yet enough to make the entry price attractive. If the rollout disappoints or earnings growth falls short, that premium could leave less room for error. (Seeking Alpha)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2026.

Haemonetics Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

Haemonetics Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.